Rhythm Pharma reports positive Phase 2 setmelanotide data in PWS; plans Phase 3

RHYTHM PHARMACEUTICALS, INC.

18 patients enrolled; 17 remain on therapy; safety consistent with known profile.
6 of 8 patients at Month 3 achieved BMI reduction; 3 of 5 at Month 6 saw BMI reduction.
6 of 7 evaluable patients at Month 3 had meaningful hyperphagia (HQ-CT) score reduction.
Company plans to advance setmelanotide into Phase 3 registrational trial in PWS.
Initiated Phase 1 Part D of weekly MC4R agonist RM-718 in up to 20 PWS patients.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.